In the previously described LOCAT study in which gemfibrozil reduced the development of new bypass graft lesions, gemfibrozil increased HDL levels and led to a 36% reduction in triglyceride levels (P<0.001).156 To date, no trial has investigated the use of fenofibrate ther- apy to reduce triglyceride levels and to potentially improve outcomes after CABG, highlighting the need for more research on the subject. For CABG patients with severely elevated tri- glyceride levels >500 mg/dL, fenofibrate therapy should be administered in addition to statin therapy to help prevent The use of combination fenofibrate-statin therapy may also be considered in diabetic patients recover- ing from CABG who have high triglyceride levels and low HDL cholesterol levels that persist despite statin therapy,141 as indicated by post hoc subgroup analyses from the FIELD and Lipid Management Recommendations 1. Unless contraindicated, all CABG patients should receive statin therapy, starting in the preoperative period and restarting early after surgery (Class I; Level of Evidence A). 2. High-intensity statin therapy (atorvastatin 40 80 mg, rosuvastatin 20 40 mg) should be administered after surgery to all CABG patients <75 years of age (Class I; Level of Evidence A). 3. Moderate-intensity statin therapy should be adminis- tered after CABG for those patients who are intoler- ant of high-intensity statin therapy and for those at greater risk for drug-drug interactions (ie, patients >75 years of age) (Class I; Level of Evidence A). 4. Discontinuation of statin therapy is not recommended before or after CABG unless patients have adverse reactions to therapy (Class III; Level of Evidence B). -Blocker Therapy Activation of the adrenergic nervous system to excessive lev- els contributes to the pathophysiology and symptoms of many cardiovascular diseases. -Blockers are competitive antago- nists at the -adrenergic receptors, thus modulating activities in this pathway. 